STING1 and neoplasm: Clinical trials are testing agonists of STING-nucleotide, with direct microinjection in the tumor of a synthetic cyclic dinucleotide (CDN) derivative that activates all human STING alleles (Corrales et al., 2015; Flood et al., 2019).